Latigo Biotherapeutics posts Q2 FY26 net loss of $25.8 million; G&A expenses rise 64.29% to $4.6 million

LTGO•2026-09-03

Clinical trial plans

Latigo plans Phase 3 onzotrigine trials in the second half of 2026 and expects topline bunionectomy and safety data in the second half of 2027.

Q2 FY26 results and expenses

Latigo Biotherapeutics posted a net loss of USD 25.8 million for Q2 2026, unchanged from Q2 2025.

Research and development expense slipped 7.42% to USD 21.2 million, while general and administrative expense climbed 64.29% to USD 4.6 million.

Cash position and IPO proceeds

Cash and cash equivalents totaled USD 55 million at June 30, 2026; net IPO proceeds are expected to fund operations into 2029.

The company completed an upsized IPO in August, raising USD 397.4 million in gross proceeds, including the full underwriters’ option exercise.

Sources

Latigo Biotherapeutics posts Q2 FY26 net loss of $25.8 million; G&A expenses rise 64.29% to $4.6 million

Sec

Latigo Biotherapeutics posts Q2 FY26 net loss of $25.8 million; G&A expenses rise 64.29% to $4.6 million

Clinical trial plans

Q2 FY26 results and expenses

Cash position and IPO proceeds

Related News

Coinbase director Frederick R. Wilson reports sale of 10,000 common shares worth $1.79 million

US diesel prices hit record high as conflicts intensify supply crunch

Inflection Point Acquisition V shareholders voted on business combination proposals at extraordinary meeting

Sources

Latigo Biotherapeutics posts Q2 FY26 net loss of $25.8 million; G&A expenses rise 64.29% to $4.6 million

SmartStop Self Storage REIT declares September dividend of $0.13 a share

American Water’s Missouri unit completes USD 34.5 million purchase of Neosho water, wastewater systems